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Abstract
Background: Adverse drug events (ADEs) detection and assessment is at the center of pharmacovigilance. Data mining of
systems, such as FDA’s Adverse Event Reporting System (AERS) and more recently, Electronic Health Records (EHRs), can aid
in the automatic detection and analysis of ADEs. Although different data mining approaches have been shown to be
valuable, it is still crucial to improve the quality of the generated signals.
Objective: To leverage structural similarity by developing molecular fingerprint-based models (MFBMs) to strengthen ADE
signals generated from EHR data.
Methods: A reference standard of drugs known to be causally associated with the adverse event pancreatitis was used to
create a MFBM. Electronic Health Records (EHRs) from the New York Presbyterian Hospital were mined to generate
structured data. Disproportionality Analysis (DPA) was applied to the data, and 278 possible signals related to the ADE
pancreatitis were detected. Candidate drugs associated with these signals were then assessed using the MFBM to find the
most promising candidates based on structural similarity.
Results: The use of MFBM as a means to strengthen or prioritize signals generated from the EHR significantly improved the
detection accuracy of ADEs related to pancreatitis. MFBM also highlights the etiology of the ADE by identifying structurally
similar drugs, which could follow a similar mechanism of action.
Conclusion: The method proposed in this paper provides evidence of being a promising adjunct to existing automated ADE
detection and analysis approaches.
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Introduction
The main objective of pharmacovigilance involves the collec-
tion, monitoring, assessment and evaluation of adverse effects of
medications and other biological products from healthcare
providers and patients. There are different Spontaneous Reporting
System (SRS) databases, such as the FDA’s Adverse Event
Reporting System (AERS) [1], the European Medicines Agency
(EMA) [2] and the World Health Organization (WHO) interna-
tional database [3] that have been designed to collect reports of
suspected adverse drug events (ADEs) for these purposes. Despite
their success and strengths they have some limitations [4]. As an
example, the number of patients at risk who are taking a drug
cannot be determined, adverse reactions are underreported, and
reporting is biased. Clinical information in Electronic Health
Records (EHRs) has emerged as a new source that can provide
important information to complement and improve drug safety
surveillance strategies [5,6]. It is believed that the integration of
diverse information sources can lead to an improved surveillance
system [7,8].
Different data mining algorithms (DMAs) [5,9], based on
disproportionality analysis (DPA) have been developed to assist in
identifying safety signals in pharmacovigilance databases of
potentially novel ADEs that merit further investigation. However,
signals generated through DMAs based on EHR data also have
some limitations and challenges that are different from those
associated with SRS data. EHR data consists of information
associated with the process of care, which is not focused on the
reporting of adverse events, and therefore ADEs are often sparse
in EHR data and occur much less frequently than other types of
clinical information, such as treatments, disorders, and symptoms.
In addition, drug-ADE relations are typically not expressed
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explicitly in EHRs, and DMA methods based on co-occurrence in
a report are used to find associations from a broad variety of
information in the patient reports, such as treatment indications,
co-morbidities, other symptoms or medications. Therefore, the
statistically-based associations between a drug and an adverse
event (AE) represent drug-AE relations that are not necessarily
ADEs, such as treatment relations. Since use of the EHR for
pharmacovigilance is a relatively new area of research, it would be
useful to develop and evaluate new methods to enhance the
accuracy of signals generated through EHR-based DMAs.
In previous work, we demonstrated that molecular similarity
analysis is a valuable tool to improve the accuracy DPA based
ADE detection in AERS [10]. Exploiting the premise widely
accepted in medicinal chemistry that similar molecules can have
similar biological properties [11], the drugs determined by the
model as being structurally similar to an ADE reference standard
set, could cause the same ADE following a similar pharmacolog-
ical mechanism. In this article, we showed that the application of
MFBM can be easily extended to ADE detection based on EHR
data. Our results demonstrate that the integration of both
methodologies facilitates the detection of the ADE pancreatitis.
Materials and Methods
Ethics Statement
New York Presbyterian Hospital Electronic Health Records
were analyzed after obtaining IRB approval from Columbia
University Medical Center committee (consent was given through
waiver of authorization; protocol number: IRB-AAAD6669).
Materials
EHR data. The EHR data included approximately 1.2 mil-
lion narrative patient notes from 2004 to 2010. Admission notes,
discharge summaries and outpatient visits for a total of approx-
imately 178,000 patients at New York Presbyterian Hospital were
analyzed after obtaining IRB approval.
Reference standard dataset. A reference standard of 253
drugs reported to cause the ADE pancreatitis was collected.
Information in the reference standard was compiled from
Micromedex/Drugdex, review articles, case reports, and reliable
websites (the complete dataset and the references are given in
Table S1). Drugs following two inclusion criteria were taken into
account in the reference standard: 1) well-established by Micro-
Figure 1. Flowchart of the ADE detection process for pancreatitis.
doi:10.1371/journal.pone.0041471.g001
Enhancing Adverse Drug Event Detection
PLoS ONE | www.plosone.org 2 July 2012 | Volume 7 | Issue 7 | e41471
medex (a trusted medical database), or by literature reviews or
reports where the pancreatitis follows a reasonable temporal
sequence from administration of the drug and the ADE is
confirmed by de-challenge/re-challenge (cessation of the drug and
the symptoms and new exposure to the drug and reappearance of
the symptoms); 2) probable/possible where the drug is considered
be responsible for the adverse effect but other possible causes are
not totally excluded (more information is provided in Table S1).
Drug structure. The DrugBank database [12] was used to
obtain the structures of drugs included in this study. Some drugs
whose structures were not available in DrugBank were manually
represented using the Molecular Operating Environment (MOE)
software [13].
Methods
An overview of the different steps is shown in Figure 1, and a
more detailed description is provided below: first, unstructured
narrative and structured laboratory data from the EHR is
processed to generate a set of candidate-drugs associated with
pancreatitis using DPA. The molecular fingerprints are computed
and the similarity of structures of the candidate-drugs are
compared to the structures in our reference standard set through
MFBM providing more evidence of a possible novel ADE that
would be of interest to study further.
EHR data mining. The natural language processing (NLP)
system MedLEE [14] was used to process the unstructured
narrative data, and to extract and normalize relevant clinical
entities, such as medications, diseases, symptoms, and associated
temporal information. In addition, structured data was also
obtained, consisting of abnormal laboratory test results that were
associated with pancreatitis. Determining the pancreatitis outcome
was based on laboratory test values [15,16], which were extracted
from structured EHR data (amylase $300 U/L or lipase
$120 U/L), as these values are standardly used to determine
potential occurrences of pancreatitis. Drug names were standardized
and mapped to UMLS codes using MedLEE [14], and then
generic names were obtained using RXNORM [17]. As an
example, the brand name Videx was extracted from a note and
then mapped to the UMLS code C0592249 by MedLEE, and
subsequently RXNORM was used to map it to the generic name
didanosine (UMLS code C0012133). A detailed process has been
described in previous publications [18,19]. The standard DPA
method using the Odds Ratio (OR) measure was used to generate
signals consisting of statistical associations between drugs and the
event pancreatitis [9,20]. DPA is based on frequency analysis
consisting of 262 contingency tables containing drug-event pairs.
OR is a measure of association between drugs and adverse events
that can be calculated from the contingency table [9,20].
Associations were quantified by the lower 5th percentile of the
Odds Ratio measure (OR05) [9]. To qualify as signals, associations
had to meet two criteria: (1) OR05.1.25; (2) associations must
pass a statistical test of independence P-value ,0.05, based on the
one-sided Fisher exact test and a Bonferroni correction, a
conservative adjustment for multiple comparisons.
Molecular fingerprint-based modeling (MFBM). The
development process of this type of MFBM has been described
in more detail in our previous publication [10]. The structures of
the drugs involved in this study (i.e., the drugs in the reference
standard and the candidate drugs generated by DPA method)
were downloaded from the DrugBank database [12] and subjected
to different preprocessing steps with the module Wash in the
Molecular Operating Environment (MOE) software [13]. In this
module, simple metal salts were disconnected and only the active
ingredient was retained (i.e. the largest molecular fragment), the
protonation state was considered neutral and explicit hydrogen
atoms were added.
In the next step, four different molecular fingerprints were
calculated for the drugs using the software MOE to carry out a
comparative study of their performances: a) MACCS (MACCS
structural keys), b) TGD (Typed Graph Distances), c) TGT (Typed
Graph Triangles) and d) GpiDAPH3 (Graph 3-Point Pharmaco-
phore) [13]. The basic idea is to represent a molecule using a bit
vector that codifies the existence or absence of structural features,
functional groups, pharmacophore features or molecular proper-
ties [21–25]. All the molecular fingerprints were calculated from
the 2D molecular graph. MACCS fingerprints codify 166
structural keys. As an example, using MACCS fingerprints, some
substructures represented in the molecule C7H13-NH2 are: bit 19-
seven membered ring, bit 84-NH2 (amine group). TGD is a 2-
point pharmacophore fingerprint codifying pair of atoms using
graph distance and two atom types (the atom type could be donor,
acceptor, polar, anion, cation, hydrophobe). TGT is a similar
fingerprint but codifies triplets of atoms (3-point pharmacophore).
GpiDAPH3 also codifies 3 pharmacophoric features calculated
from the 2D molecular graph. All triplets of atoms are coded using
graph distances and atom types (there are 8 possible atom types).
The final step consisted of similarity assessments between
fingerprints of pairs of drugs using the Tanimoto coefficient (TC)
measure of similarity. TC, also known as the Jaccard index, is one
of the measurements most widely applied in the scientific literature
for measuring similarity [24]. The range for the TC covers values
from 0 to 1, where 0 means ‘‘minimum similarity’’ and 1 means





where NA is the number of features present in fingerprint A, NB is
the number of features present in fingerprint B, and NAB is the
number of features present in both fingerprints A and B.
To compare a test set of drugs against the reference standard set
of drugs known to cause pancreatitis, a similarity matrix file based
on TC for all the drugs was calculated using the Fingerprint
Cluster module and the sim_matrix2txt.svl script in MOE [13].
Therefore Simij is the similarity score (TC values) between the ith
drug and the jth drug in the matrix. The final similarity scoring
provided by the model for a drug in the test is defined as the
maximum pairwise TC obtained against each drug in the
pancreatitis reference standard set. As an example, the drug entecavir
in the test set was compared through TC to all the drugs in the
reference standard and the maximum TC was considered the final
score pointing out that the most similar drug in the reference
standard was ganciclovir.
Evaluation. Performance evaluation of the method using
DPA by itself [9] was compared to the method that combined
DPA with MFBM. The evaluation centered on the proportion of
true signals identified by each of the approaches based on the
reference standard.
DPA by itself. The evaluation of DPA by itself was based on
comparing the drugs that were selected with OR05 value greater
than the previously established cutoff of 1.25 with the drugs in the
pancreatitis reference standard dataset. Since only associations
above the estimated cut-off were taken into account, the ROC
curve cannot be plotted with all the drugs included in the EHR.
For this reason the precision of the method (TP/TP+FP) was
calculated as a standard comparative measurement of the
performance. The method was compared to random results
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PLoS ONE | www.plosone.org 3 July 2012 | Volume 7 | Issue 7 | e41471
through one-sided Fisher’s exact test using the DrugBank database
[12] as a resource, as explained below in Results.
Combination of DPA and MFBM. All the drug candidates
highlighted using DPA were subjected to MBFM-based analysis.
As described previously, a comparison between molecular
fingerprints from candidates selected by OR05 and the reference
standard set of drugs was carried out through the calculation of the
Tanimoto coefficient (TC). The maximum pairwise TC obtained
against each drug in the pancreatitis reference standard set was
considered to be the final similarity score.
The performance of the MFBM was assessed through a leave-
one-out cross validation method. Each drug included in both sets
(candidates selected through OR05 and already included in the
reference standard set) was taken out and evaluated by the model
in order to compare the performance with the rest of the candidate
drugs selected by OR05. Precision-Recall and Receiver Operating
Characteristic (ROC) curves were plotted, considering as true
positives the drugs included in our reference standard and false
positives the rest of candidate drugs.
When evaluating performance, the false positives according to
our system are drugs not included in our reference standard.
Nevertheless, it is possible that some of the drugs selected and not
included in the reference standard are causally related to
pancreatitis. For this reason, a bibliographic search using Micro-
medex/Drugdex database [26,27] and case reports from the
literature was carried out to confirm whether the drugs found by
the method but not included in the reference standard dataset
could be the cause of the adverse event under study (see Table S2).
A final evaluation of the combined model has been completed for
this test set through Precision-Recall and ROC curves.
Results
Performance of DPA
The EHR from New York Presbyterian Hospital was mined
looking for associations between drugs and the adverse event
pancreatitis, and 278 drugs were found to be associated with the
ADE using the DPA method by itself. Of those, 99 drugs were
already included in the pancreatitis reference standard dataset
established previously (see Tables S1 and S2). The precision of the
method was calculated as the ratio of true positive cases divided by
all the positive cases (Precision = TP/(TP+FP)). The overall
precision of the EHR analysis is 0.36. The method was compared
to random results using the DrugBank database [12], containing
1660 approved drugs (small drugs, biotech and nutraceuticals).
Based on expectation, if a random subset of 278 drugs in
DrugBank was selected, 42 drugs included in the reference
standard would be found. The estimated precision of a method
that randomly selects drug candidates was 0.15. The p-value for
the probability that Disproportionality Analysis (DPA) identified 99
reference standard drugs in the subset of 278 candidates is very
unlikely (p,.001). Table 1 shows the performance of DPA at
different top positions. These results point out the usefulness of the
application of EHR in the detection of adverse events in drugs,
since 99 out of 278 associations were found in the pancreatitis
reference standard database. However, if the Precision-Recall and
Receiver Operating Characteristic (ROC) curves are plotted for
the 278 candidates using OR05 as the scoring function, it is
possible to observe that the precision of the method barely
improves in top positions (see Table 1 and Figure 2). Nevertheless,
as it is explained in the next section, an improvement in ADE
detection is still possible through the combination of DPA with
MFBM techniques.
Performance Improvement by Combining DPA with
MFBM
An improvement of the precision of the method in top
ranking positions can be achieved through the combination of
DPA with MFBM. As described in the Methods section,
different fingerprints were calculated for all the drugs used in
the study. The fingerprints of the set of candidate drugs selected
by Disproportionality Analysis (DPA) were compared to the
fingerprints of drugs in the pancreatitis reference standard dataset
through the Tanimoto coefficient (TC). Drugs included in both
groups (in EHR and already in the reference standard) were
taken out one by one (leave-one-out method) and evaluated by
the MFBM. Precision in different top positions was calculated
for all the MFBMs (see Table 1). The precision of the method
improves when the combined methodology is used. A two-fold
enrichment factor is achieved when a subset of 50 top drug-
candidates are evaluated by MACCS fingerprints (see Table 1).
Within the top 50 drugs selected by MACCS, 37 drugs were
estimated as true positives (TP) and 13 drugs were found false
positives (FP). The probability that the method identified 37
drugs by chance is highly unlikely (p-value,.001; one-sided
Fisher’s exact test). Precision-recall and ROC curves for all 278
drug candidates selected by DPA was also plotted to show the
comparative performance for the different calculated fingerprints
(Figure 2). It is worth noting that although the precision of DPA
is constant within this set of candidates, the method is still very
useful for obtaining this first set of 278 candidate drugs related
to pancreatitis (99 out of 278 drugs were already included in the
pancreatitis reference standard set). However, an improvement of
the precision in top positions was achieved by prioritizing the
candidates generated through DPA with MFBMs.
A second evaluation of the combined model was completed
identifying pancreatitis case reports in the literature and Micro-
medex/Drugdex database [26,27] for the drugs selected in EHR
but not included in the pancreatitis reference standard (see Table
S2). Out of 179 drugs not included in the pancreatitis reference
standard, 21 were considered a possible cause of pancreatitis and
158 were considered negative cases since no consistent information
relating the drugs as the cause of the adverse event was found.
Although further research will be necessary to confirm the ADE
for some cases in this test set, the evaluation according to the
combined method HER + MFBM provides more insights about
the accuracy of the system. The overall precision in this test set is
lower since the drugs included in the reference standard are not
taken into account in the analysis. As shown in Figure 3, through
Precision-recall and ROC plots considering this test set (21 true
positives versus 158 false positives), the curves provided by
MACCS and GpiDAPH3 fingerprints offer the best results in
the precision improvement compared to DPA and alternative
molecular fingerprint representations.
Rationalization of the Signals Generated in EHR
The application of similarity models applied to EHR data
provides a new system to rank scores of the detected associations
based on the maximum similarity to a drug in the reference
standard. In this manner, the drug source in the reference
standard is identified by the model, for which some reports relating
the drug to the adverse event were previously found. This fact
facilitates the ADE evaluation process depending on the available
information for the similar drug in the reference standard. The
model also can help to point out different hypotheses about
possible mechanisms of action. Some examples of pancreatitis
candidate drugs not included in the reference standard identified
by the combined model and with some level of evidence in the
Enhancing Adverse Drug Event Detection
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literature are described in the next section (see Table S2 for a more
detailed description).
Examples of drugs belonging to the same
pharmacological category. An example of a drug not
included in the initial pancreatitis reference standard set is megestrol,
Figure 2. Receiver Operating Characteristic (ROC) (a) and Precision-Recall (b) curves evaluating the set of 278 EHR ADE candidates
with OR05 and different MFBMs. It is worth noting that although OR05 algorithm is very useful to originate the first set of 278 candidate drugs
related to pancreatitis (99 out of 278 drugs were already included in the pancreatitis reference standard set), the precision of the method is constant
within this set. However, an improvement of the precision in top positions can be achieved using MFBM (in the graphic: black-OR05, red-MACCS,
green-GpiDAPH3, yellow-TGT, blue-TGD).
doi:10.1371/journal.pone.0041471.g002
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a progesterone derivative with antineoplastic properties used in the
treatment of carcinoma. According to our MFBM, megestrol is
structurally similar to norethindrone, another progestogen drug used
as oral contraceptive included in the reference standard (see
Table 2 and Table S2). There are some publications that relate the
drug norethindrone as a possible cause of pancreatitis with positive
rechallenge [28]. Although not many reports were found relating
megestrol as the cause of pancreatitis, some information is available
establishing pancreatitis as a possible adverse event due to the use of
contraceptive pills containing megestrol [29,30]. However, further
studies will be necessary to explain the potential adverse event in
the drug.
Entecavir is a nucleoside analog used in clinic as an antiviral for
the treatment of hepatitis B. A possible role of entecavir in the
development of pancreatitis has been discussed previously [31].
Elevations in serum amylase were also reported in patients
receiving entecavir although no clinical pancreatitis was diagnosed
[32]. Our system detected a structural similarity between entecavir
and ganciclovir, another antiviral drug used to treat cytomegalovirus
infections which was included in the reference standard because it
was identified in the literature and in Micromedex causally related
to pancreatitis [26,33].
Another case found in the EHR associated with pancreatitis is the
polyene antifungal antibiotic drug amphotericin B. This drug was
also detected by MFBM as a drug similar to doxorubicin, an
anthracycline antibiotic used in clinic in the treatment of different
types of cancer (see Table 2). Although amphotericin B could be the
treatment for fungal infections associated to pancreatitis, there are
some reports in the literature that confirm the potential risk of this
drug. A report describes an increased serum lipase levels with
clinical signs of pancreatitis in some patients treated with liposomal
amphotericin B therapy [34]. Another report describes a case of
pancreatitis in an HIV patient possibly due to amphotericin B [35].
Examples of drugs belonging to different
pharmacological categories. The combination of the DPA
and MFBM can also detect drugs that belong to different
pharmacological classes (see Table 2). An interesting example of
drug pointed out by MFBM is loperamide, a piperidine derivative
opioid-receptor agonist that is very effective for the treatment of
diarrhea. The structure of loperamide is similar to haloperidol, a drug
in the reference standard with different pharmacological category
since haloperidol is a butyrophenone belonging to antipsychotic
medications and used in the treatment of schizophrenia. There are
some reports in the literature that confirm the potential adverse
effect of lopiramide probably due to a spasm at the sphincter of Oddi
or inhibition of the release of pancreatic polypeptide [36–38]. On
the other hand, haloperidol was reported to cause pancreatitis in a
study of antipsychotic drugs inducing pancreatitis [27,39]. The
temporal relationship between the adverse event and the
beginning of the therapy could indicate a causal relationship.
Another example of similar drugs belonging to different
pharmacological classes is pyrimethamine and lamotrigine (drug
included in the reference standard). Pyrimethamine, an antiparasitic
drug used in the treatment of malaria and toxoplasmosis, is selected
by MFBM as a drug structurally related to lamotrigine (both drugs
present a chloro substituted phenyl with a diamine azine ring), an
anticonvulsant used to treat epilepsy, bipolar disorders and
depression. Pancreatitis is described as a possible ADE for the
combination pyrimethamine/sulfadoxine [40]. However, more
studies will be necessary to confirm the ADE.
An interesting case to study further is micafungin, an antifungal
drug indicated for the treatment of candidiasis by inhibiting the
production of 1,3-beta-D-glucan, an important component of the
fungal cell walls. Although fungi infections can occur to patients
with pancreatitis, and therefore the prescription of an antifungal
drug is necessary in some cases [41], there is also a report in the
literature describing a case of acute pancreatitis probably caused by
micafungin [42]. Our model detected that micafungin resembles the
peptidic structure of ceruletide (see Table 2), a drug included in our
reference standard and used in experimental animal models to
induce pancreatitis [43]. Further studies will be necessary to shed
some light about the relationship between micafungin and pancre-
atitis.
Cosyntropin, a derivative of adrenocorticotropic hormone used to
diagnose cortisol disorders, is another case selected by DPA and
MFBM as a drug related to pancreatitis. In this case, the information
gathered in Micromedex database clearly indicates that pancreatitis
is an ADE associated to the drug [26]. Cosyntropin presents some
structural similarity regardless to caspofungin, an antifungal drug
included in the reference standard set.
Table 1. Performance of DPA compared to DPA+MFBM (DPA
combined with MACCS, GpiDAPH3, TGD and TGT molecular
fingerprints) in different TOP positions.
Number of reference standard drugs in different TOP positions
DPA+MACCS DPA+GpiDAPH3 DPA+TGD DPA+TGT DPA
TOP-10 9 8 5 6 4
TOP-25 20 20 14 16 10
TOP-50 37 30 23 28 20
TOP-75 47 44 34 36 31
TOP-100 52 51 48 46 38
TOP-125 62 60 56 59 46
TOP-150 66 67 63 63 55
Precision in different TOP positions
DPA+MACCS DPA+GpiDAPH3 DPA+TGD DPA+TGT DPA
TOP-10 0.90 0.80 0.50 0.60 0.40
TOP-25 0.80 0.80 0.56 0.64 0.40
TOP-50 0.74 0.60 0.46 0.56 0.40
TOP-75 0.63 0.59 0.45 0.48 0.41
TOP-100 0.52 0.51 0.48 0.46 0.38
TOP-125 0.50 0.48 0.45 0.47 0.37
TOP-150 0.44 0.45 0.42 0.42 0.37
Enrichment factor in different TOP positions
DPA+MACCS DPA+GpiDAPH3 DPA+TGD DPA+TGT DPA
TOP-10 2.53 2.25 1.40 1.68 1.12
TOP-25 2.25 2.25 1.57 1.80 1.12
TOP-50 2.08 1.68 1.29 1.57 1.12
TOP-75 1.76 1.65 1.27 1.35 1.16
TOP-100 1.46 1.43 1.35 1.29 1.07
TOP-125 1.39 1.35 1.26 1.33 1.03
TOP-150 1.24 1.25 1.18 1.18 1.03
doi:10.1371/journal.pone.0041471.t001
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Discussion
This main goal of this study is to demonstrate the usefulness of
the analysis of the molecular structure to improve the precision
and rationalization in the detection of drug-pancreatitis associations
found in EHR. Although structure similarity analysis was applied
to the EHR in this study, the method could be applied to other
pharmacovigilance databases created to analyze postmarketing
drug safety information, such as AERS, WHO or EMA. In fact,
the results shown are in accordance with a previous publication
analyzing the adverse event rhabdomyolysis from the point of view of
AERS and molecular structure similarity [10].
Figure 3. Receiver Operating Characteristic (ROC) (a) and Precision-Recall (b) curves evaluating the test set of EHR pancreatitis
candidates (in the graphic are not included the drugs already in the reference standard: 21 true positives versus 158 false
positives, black-OR05, red-MACCS, green-GpiDAPH3, yellow-TGT, blue-TGD).
doi:10.1371/journal.pone.0041471.g003
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MFBM permits the rationalization of ADE signals detected in
pharmacovigilance databases through the identification of struc-
turally similar drugs by which ADE information has been already
published. This can be useful to estimate the importance of the
signal generated in EHR to make decisions regarding further
follow-up. The system can be used along with other pharmacov-
igilance methods to provide additional information and evaluate
the potential relevance of the signals, such as biological and
pharmacological plausibility.
The nature of the system permits the identification of drugs
belonging to different pharmacological classes than the drugs
included in the reference standard ADE dataset, although it is more
likely the identification of drugs with similar pharmacological
profiles, which can still present utility in the case of researchers not
related to pharmacological backgrounds.
Although MFBM by itself can present some limitations in the
detection of complex clinical adverse events due to the different
biological mechanisms involved in ADEs with high molecular
variability [10], the different nature regarding the databases used
for pharmacovigilance, allows the combination of both methods to
improve ADE detection by generating sets of drugs with enhanced
enrichment factors. Since the model is based on the structural
comparison against a reference standard dataset of drugs
responsible for the ADE under study, the results offered by the
models are directly dependent on the quality of the reference
standard. This dataset should contain a heterogeneous represen-
tation of the different structural drug classes related to the ADE
and be as complete as possible.
Molecular fingerprints have been widely validated in previous
publications and it has been shown that they are very useful to
recognize similar molecules in large databases [21–25]. However,
some molecular fingerprints could recognize as similar two
structurally different molecules when they present the same
substructural or pharmacophoric features differently reorganized
at molecular level. Nevertheless, this case would be interesting
since the same collection of substructures could also determine
similar pharmacological and distribution profiles.
In the current study, the performances of different 2D
fingerprints analyzing the molecular structure from diverse points
of view were described. However, alternative methods using other
types of fingerprints or molecular descriptors could still be
explored [44,45]. Another possibility for further study is the
construction of similar models taking into account the 3D most
stable conformation in drugs [46]. Nevertheless, although 2D
methods are considered more limited than 3D methods, they still
present good results and it is possible to avoid complex steps, such
as the selection of bioactive drug conformations, calculation of the
3D most stable conformers and superimposition of the final
structures to compare their similarity.
Conclusions
The combination of EHR analysis and structural similarity data
led to an improved prioritization of drug candidates related to the
adverse event pancreatitis. A set of drugs was selected using the
combination of both techniques to further study their possible
causal relationship to pancreatitis. The results obtained in this study
are in accordance with a previous publication analyzing the
adverse event rhabdomyolysis [10]. Structural similarity analysis
could be used as a useful tool to analyze and rationalize data
extracted from pharmacovigilance databases. The implementation
of molecular structure data can facilitate adverse drug event
detection.
Supporting Information
Table S1 Reference standard of 253 drugs reported to
cause the ADE pancreatitis.
(XLSX)
Table S2 Drug candidates selected in EHR. Similarity
against the pancreatitis reference standard dataset is
provided through Tanimoto coeficcient (TC) and differ-
ent fingerprints (TGT, GpiDAPH3, TGD, MACCS).
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Table 2. Examples of candidates selected through the combination of DPA and MFBM (MACCS fingerprints) and similar molecules
in the pancreatitis reference standard, along with OR05 (lower 5th percentile of the Odds Ratio measure of association in DPA
analysis) and TC (Tanimoto coefficient) values.
EHR+MFBM drug candidate
Most similar drug in the pancreatitis reference
standard TC OR05
Same pharmacological category
Megestrol Norethindrone 0.84 1.82
Entecavir Ganciclovir 0.78 2.23
Amphotericin B Doxorubicin 0.75 3.83
Different pharmacological category
Loperamide Haloperidol 0.79 2.60
Pyrimethamine Lamotrigine 0.78 2.31
Micafungin Ceruletide 0.76 3.68
Cosyntropin Caspofungin 0.76 3.39
Different level of pancreatitis-causal information was found for the candidate drugs in the literature.
doi:10.1371/journal.pone.0041471.t002
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